Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir amibufenamide in elderly chronic hepatitis B patients
ChiCTR2200064306Phase 4Not yet recruiting
- Sponsor
- Linyi People's Hospital
- Start
- Aug 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir + amibufenamide in Chronic Hepatitis B (CHB), sponsored by Linyi People's Hospital. Primary endpoints: HBV DNA, Biochemical tests and 3 more. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
tenofovir + amibufenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200064306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064306.